SEC Form 4 · accession 0001472343-17-000022
Roka BioScience, Inc. · ROKA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lars Boesgaard
Officer — Vice President, CFO
Period of report
Mar 24, 2017
Accepted (ET)
Mar 28, 2017 · 4:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001472343
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common stock, par value $0.001 per shareF1 | $3.45 | Mar 24, 2017 | A | 54,000 | A | — | Mar 23, 2027 | Common Stock | 54,000 | 54,000 | D |
Explanation of responses
- F1Such stock options vest 25% on March 24, 2018 and in twelve equal increments on a quarterly basis beginning three months after that. The stock options have a term of ten years.